,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-10-18 08:47:00,The Zacks Research Daily presents the best research output of our analyst team.,0.6325156092643738,0.012341027148067951,0.35514333844184875,positive,0.6201745867729187
1,2018-10-18 08:47:00,"Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA).",0.048359647393226624,0.007589536253362894,0.9440507888793945,neutral,0.04077010974287987
2,2018-10-18 08:47:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
3,2018-10-18 08:47:00,"You can see all oftoday's research reports here >>>

AstraZeneca 's shares have gained +8% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry which has gained +3.2% over the same period.",0.9561288356781006,0.024030210450291634,0.019841020926833153,positive,0.9320986270904541
4,2018-10-18 08:47:00,"AstraZeneca's newer drugs like Lynparza, Tagrisso and Brilinta should keep contributing to the top line while several launches are underway across each of the therapeutic areas, Oncology, CV metabolism and Respiratory.",0.6471381187438965,0.011615416966378689,0.34124645590782166,positive,0.635522723197937
5,2018-10-18 08:47:00,"Meanwhile, cost-cutting initiatives should drive the bottom line.",0.789933979511261,0.01989092119038105,0.1901751458644867,positive,0.7700430750846863
6,2018-10-18 08:47:00,AstraZeneca also has a promising late-stage pipeline that includes immuno-oncology candidates.,0.7604093551635742,0.01021086797118187,0.2293797880411148,positive,0.750198483467102
7,2018-10-18 08:47:00,Imfinzi is a key drug in the pipeline.,0.5964526534080505,0.011978847905993462,0.39156854152679443,positive,0.5844737887382507
8,2018-10-18 08:47:00,The company has a positive record of earnings surprises in the recent quarters.,0.9466361999511719,0.02157570794224739,0.03178815543651581,positive,0.925060510635376
9,2018-10-18 08:47:00,Estimates have remained stable ahead of the company's Q3 earnings release.,0.6195075511932373,0.030395733192563057,0.3500966727733612,positive,0.5891118049621582
10,2018-10-18 08:47:00,"Nevertheless, AstraZeneca's core products like Nexium, Crestor and Seroquel are facing generic competition, which is hurting sales growth.",0.019953632727265358,0.9659141302108765,0.014132155105471611,negative,-0.945960521697998
11,2018-10-18 08:47:00,The diabetes franchise also faces stiff competition while pricing pressure is hurting sales in the Respiratory franchise.,0.019698699936270714,0.9649874567985535,0.015313823707401752,negative,-0.9452887773513794
12,2018-10-18 08:47:00,(You can read the full research report on AstraZeneca here >>> ).,0.012752898968756199,0.012103277258574963,0.9751437902450562,neutral,0.0006496217101812363
13,2018-10-18 08:47:00,"Strong Buy-rated Salesforce 's shares have gained +38.9% so far this year, handily outperforming the Zacks Computer - Software industry which gained +19% over the same period.",0.9558688998222351,0.025128671899437904,0.019002359360456467,positive,0.930740237236023
14,2018-10-18 08:47:00,Salesforce's diverse cloud offerings and strong spending on digital marketing remain the catalysts.,0.8468379378318787,0.011960097588598728,0.14120198786258698,positive,0.8348778486251831
15,2018-10-18 08:47:00,Management is extremely optimistic about enhancement of customer experience that has aided growth of the cloud segment.,0.9219916462898254,0.012629857286810875,0.06537846475839615,positive,0.9093617796897888
16,2018-10-18 08:47:00,"Additionally, strategic acquisitions and the resultant synergies are anticipated to prove conducive to growth over the long run.",0.9254710078239441,0.013231851160526276,0.0612972192466259,positive,0.912239134311676
17,2018-10-18 08:47:00,"Furthermore, the company's move of utilizing other data center operators like Amazon and Alphabet's geographical reach to expand its international business is commendable and will help it in achieving its targeted $23 billion sales mark by 2022.",0.9440549612045288,0.01475099939852953,0.04119410738348961,positive,0.9293039441108704
18,2018-10-18 08:47:00,"However, stiff competition, currency fluctuations and an increase in investments for international expansions and data centers could negatively impact near-term profitability.",0.02900855615735054,0.9142323136329651,0.056759193539619446,negative,-0.8852237462997437
19,2018-10-18 08:47:00,(You can read the full research report on salesforce.com here >>> ).,0.012672662734985352,0.012606617994606495,0.9747206568717957,neutral,6.604474037885666e-05
20,2018-10-18 08:47:00,"Shares of Mastercard have increased +37.3% over the past year, significantly outperforming the Zacks Financial Transaction Services industry's rally of +22.2%.",0.9597451090812683,0.02216029353439808,0.018094610422849655,positive,0.9375848174095154
21,2018-10-18 08:47:00,"The company is poised for growth, given its solid market position, ongoing expansion and digital initiatives plus significant opportunities from the secular shift toward electronic payments.",0.9140021800994873,0.013170740567147732,0.07282701134681702,positive,0.9008314609527588
22,2018-10-18 08:47:00,"The buyouts of VocaLink and NuData Security complement efforts to participate in new payment flows, and enhance safety and security offerings.",0.9405254125595093,0.014455839060246944,0.045018672943115234,positive,0.9260695576667786
23,2018-10-18 08:47:00,The company has seen the Zacks Consensus Estimate for 2018 earnings being revised upward over the last 60 days.,0.747044026851654,0.06400098651647568,0.18895508348941803,positive,0.6830430626869202
24,2018-10-18 08:47:00,"However, escalating costs, higher incentives and rewards will put pressure on its bottom line.",0.5054378509521484,0.34674695134162903,0.14781519770622253,positive,0.1586908996105194
25,2018-10-18 08:47:00,(You can read the full research report on Mastercard here >>> ).,0.013421451672911644,0.011832918971776962,0.9747455716133118,neutral,0.0015885327011346817
26,2018-10-18 08:47:00,"Other noteworthy reports we are featuring today include Eni (E), Lam Research (LRCX) and Koninklijke Philips (PHG).",0.03805677592754364,0.005248459987342358,0.9566947817802429,neutral,0.03280831500887871
27,2018-10-18 08:47:00,Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time.,0.814492404460907,0.0160694383084774,0.1694381833076477,positive,0.7984229922294617
28,2018-10-18 08:47:00,It's a once-in-a-generation opportunity to invest in pure genius.,0.5448517799377441,0.011377338320016861,0.4437708854675293,positive,0.5334744453430176
29,2018-10-18 08:47:00,Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings.,0.1108352467417717,0.007436841260641813,0.881727933883667,neutral,0.1033984050154686
30,2018-10-18 08:47:00,He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports.,0.026142945513129234,0.011532393284142017,0.9623246192932129,neutral,0.014610552228987217
31,2018-10-18 08:47:00,"If you want an email notification each time Sheraz publishes a new article, please click here>>>

Per the Zacks analyst, acquiring existing stores and opening new ones at key marketplaces enables Lithia Motors to diversify its product portfolio and strengthen its luxury products offering.",0.9403840899467468,0.013807144947350025,0.04580884054303169,positive,0.9265769720077515
32,2018-10-18 08:47:00,"Per the Zacks analyst, Stanley Black gains from solid brands, like CRAFTSMAN and DeWalt.",0.9436759352684021,0.02659999020397663,0.02972409687936306,positive,0.9170759320259094
33,2018-10-18 08:47:00,"Also, buyouts of IES Attachments and MTD Products will be boons.",0.8639391660690308,0.018542200326919556,0.11751863360404968,positive,0.8453969955444336
34,2018-10-18 08:47:00,"Per the Zacks analyst, high tariffs and volatile market conditions are expected to hit Tyson Foods' Pork and Chicken volumes.",0.021114099770784378,0.9609631896018982,0.017922669649124146,negative,-0.9398490786552429
35,2018-10-18 08:47:00,"American Financial (AFG) Set to Grow on Strong Pricing

Per the Zacks analyst, American Financial is poised to benefit from consistent price increase in Property and Casualty business, niche presence in the P&C and annuity markets.",0.9506868720054626,0.015691740438342094,0.0336214043200016,positive,0.9349951148033142
36,2018-10-18 08:47:00,"Eni (E) Banks on New Oil & Gas Projects in Angola & Ghana

Start-up of new upstream projects in Angola and Ghana will support Eni's growth in oil and natural gas production, according to the Zacks analyst.",0.9245663285255432,0.012569903396070004,0.062863789498806,positive,0.9119964241981506
37,2018-10-18 08:47:00,"Per the Zacks analyst, RenaissanceRe's increasing gross premiums backed by its Casualty and Specialty, and Property segments and lower expenses led by solid operational efficiency should drive growth.",0.955928385257721,0.017291583120822906,0.026779979467391968,positive,0.9386367797851562
38,2018-10-18 08:47:00,"Per the Zacks analyst, Philips continues to benefit from growing Diagnosis & Treatment business on the back of partnerships, expanding geographical coverage and innovative solutions.",0.9383537173271179,0.013789525255560875,0.04785681143403053,positive,0.9245641827583313
39,2018-10-18 08:47:00,"Per the Zacks analyst, rising supply of office real estates in Cousin Properties' key markets will likely lower rent growth and tenant retention.",0.026908859610557556,0.9542089104652405,0.01888226717710495,negative,-0.9273000359535217
40,2018-10-18 08:47:00,"Also, higher interest rates will hamper growth.",0.01909365877509117,0.9568413496017456,0.024064945057034492,negative,-0.9377477169036865
41,2018-10-18 08:47:00,"Per the Zacks analyst, Lam Research is suffering from oversupply and overcapacity of memory chips.",0.02084462158381939,0.9605808854103088,0.01857445389032364,negative,-0.9397362470626831
42,2018-10-18 08:47:00,"Also, rising competition in semiconductor capital equipment space from Applied Materials is a risk.",0.10182508081197739,0.6121385097503662,0.2860364317893982,negative,-0.5103134512901306
43,2018-10-18 08:47:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
44,2018-10-18 08:47:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
45,2018-10-18 08:47:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
46,2018-10-18 08:47:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
